Displaying 1 - 50 of 50 tests
AML Add-On Flow Panel

Available as global and tech-only. This add-on panel is available to clarify findings on samples currently having flow cytometry analysis at NeoGenomics and is not available for stand-alone testing. Markers are cCD3, cCD22, cCD79, CD11b, CD123, CD34, CD45, CD117, cMPO, and nTdT (10 markers).

Flow Cytometry
ASXL1 Mutation Analysis

Bi-directional sequencing of the majority of exons 13 and 14 of ASXL1, corresponding to amino acids 406-1396.

Molecular
BCR-ABL1 Non-Standard p230

Real-time RT-PCR for detection of t(9;22) BCR-ABL1 fusion transcripts that result in p230 fusion proteins. Analytical sensitivity is 1 tumor cell in 100,000 normal cells. BCR-ABL1 Standard p210, p190 may be ordered as a stand-alone test.

Molecular
BCR-ABL1 Standard p210, p190

Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (E13, E14) or minor p190 (E1) fusion proteins with option to add p230 detection (micro or atypical variant). p230 testing may be ordered as a stand-alone test. For p210 and p190, analytical sensitivity is 1 tumor cell in 100,000 normal cells, log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report. For p230, results are reported as percent abnormal. Testing is New York approved for p210 and p190 only.

Molecular
BCR/ABL1 t(9;22)

Probes: ABL1 (9q34); ASS1 (9q34; BCR (22q11.2)
Disease(s): CML, ALL, MPN
Note: For suspected ALL, STAT processing is available by request. Note STAT along with MD contact name and phone number to receive STAT results.

FISH
CALR Mutation Analysis

Bi-directional sequencing of exon 9 of the CALR (calreticulin) gene with fragment length analysis for enhanced detection of low levels of insertion/deletion mutations.Testing is approved for specimens from the state of New York. Read more about the CALR Mutation Analysis.

Molecular
CBL Mutation Analysis

Bi-directional sequencing of exons 8 and 9 of the CBL gene.

Molecular
CD11cIn normal cells, CD11c is expressed on activated CD4/CD8+ T cells, granulocytes, lymphocytes, macrophages, and NK cells.

In diseased, cells, CD11c is detected on acute myeloid leukemia (AML)-M4 and M5, hairy cell leukemia, lymphoplasmacytic lymphoma (81%), small lymphocytic lymphoma (SLL), splenic lymphoma, Langerhans cell histiocytosis, sinus histiocytosis, psoriatic skin lesions, and some follicular lymphomas.
Immunohistochemistry (IHC)
CD14CD14 stains normal macrophages/monocytes, granulocytes (weak), Langerhans cells, dendritic cells, and B cells. Positive staining in diseased cells comprises B-cell chronic lymphocytic leukemia (B-CLL), follicular center cell lymphoma, diffuse large B cell lymphoma (DLBCL), and acute myeloid leukemia (AML)-M4/M5. Immunohistochemistry (IHC)
CD163CD163 antigen is restricted in its expression to the monocytic/macrophage lineage. It is present on all circulating monocytes and most tissue macrophages except those found in the mantle zone and germinal centers of lymphoid follicles, interdigitating reticulum cells and Langerhans cells. Immunohistochemistry (IHC)
CD34CD34, a single chain transmembrane glycoprotein, is selectively expressed on human lymphoid and myeloid hematopoietic progenitor cells and endothelial cells. CD34 antibody labels many gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, solitary fibrous tumor and a subset of sarcomas. CD34 staining has been also used to measure angiogenesis. Immunohistochemistry (IHC)
CD4CD4, a single chain transmembrane glycoprotein, is found on a T-cell subset (helper/inducer). It is also present on a variety of monocyte-derived cells, including Langerhans and other dendritic cells. The CD4 epitope is absent from immature thymocytes and is expressed during T-cell development. Precursor T-lymphoblastic lymphomas are therefore variable in their expression of CD4, but most mature T-cell lymphomas are positive, with the exception of aggressive NK-cell leukemia, extranodal NK-cell lymphoma, gamma delta T-cell lymphomas, and enteropathy-type T-cell lymphoma. Immunohistochemistry (IHC)
CD42bCD42b stains normal platelets, megakaryocytes, and megakaryoblasts. In diseased cells, blasts in transient myeloproliferative disorder are positively stained. CD42b is used in diagnosis of acute myeloid leukemia (AML)-M7, distinguishing AML-M7 (CD42b+) from acute myelosis with myelofibrosis (usually CD42b negative). Immunohistochemistry (IHC)
CD61CD61 (GPIIIa) is a glycoprotein found on megakaryocytes, platelets, and their precursors. CD61 antigen plays a role in platelet aggregation and also as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectrin. This antibody is useful in detecting neoplastic platelet precursors, normal platelets, and most cases of megakaryocytic leukemias. Immunohistochemistry (IHC)
CD68CD68 is an antibody directed against lysosomes. It is important for identifying macrophages in tissue sections. It stains macrophages in a wide variety of human tissues, including Kupffer cells and macrophages in the red pulp of the spleen, lamina propria of the gut, lung alveoli, and bone marrow. This antibody reacts with myeloid precursors and peripheral blood granulocytes. It shows strong granular cytoplasmic staining of chronic and acute myeloid leukemia and also reacts with true histiocytic neoplasia. It also stains granular cell tumors and some cases of melanoma, renal cell carcinoma, and pleomorphic sarcoma. Tumors of lymphoid origin are usually not stained. Immunohistochemistry (IHC)
CD71CD71 is useful in identifying erythroid precursors with no interference from mature erythrocytes and also in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome. Immunohistochemistry (IHC)
Chromosome Analysis

A wide variety of abnormalities can be identified, providing both diagnostic and prognostic information. Acute leukemias, lymphomas and chronic myeloid and lymphoid disorders are examined cytogenetically in order to establish the exact nature of the acquired genetic change. Rearrangements, also known as translocations, inversions, and deletions, can usually be detected under a light microscope. In most leukemias and lymphomas, changes in chromosome number (ploidy) or chromosome structure (rearrangements) are often observed.
 

Cytogenetics
CSF3R Mutation Analysis

Bi-directional sequencing of exons 14 and 17 of the CSF3R gene which includes detection of the common mutation T618I (also known as T595I).

Molecular
Extended Leukemia/Lymphoma Panel - 31 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD41, CD45, CD56, CD64, CD71, CD117, CD138, CD235a, FMC-7, HLA-DR, kappa, and lambda.

Flow Cytometry
Factor VIII RAFactor VIII-related antigen is a component of Factor VIII complex. Factor VIII-related antigen is one of the available immunohistochemical markers of endothelial cells. It has also been demonstrated in platelets and megakaryocytes. IHC staining of Factor VIII-related antigen is useful for diagnosis of vascular neoplasms and for identification of vascular invasion by neoplasms. Immunohistochemistry (IHC)
Glycophorin AGlycophorin A (sialoglycoprotein alpha) is one of two transmembrane proteins exposed on the outer surface of normal human erythrocytes. This monoclonal antibody reacts with an epitope located on the extracellular domain of glycophorin A and does not cross-react with glycophorin D (glycophorin delta). In normal human erythrocytes, glycophorin A is expressed during all stages of differentiation, from the normoblast to the mature erythrocyte. Once maximally expressed, the quantity of glycophorin A in each red blood cell remains constant. Glycophorin A has also been located in the blast cells of cases of erythroleukemia. Cases of acute lymphoblastic and myeloblastic leukemia are not reactive. Immunohistochemistry (IHC)
Hemoglobin AHemoglobin A antibody reacts with the alpha chain of adult hemoglobin A. This antibody is useful in the detection of red blood cell precursors. Immunohistochemical localization of hemoglobin is excellent as an erythroid marker for the detection of immature, dysplastic, and megaloblastic erythroid cells in myeloproliferative disorders, such as erythroleukemia. In contrast, myeloid cells, lymphoid cells, plasma cells, histiocytes, and megakaryocytes stain negative with anti-hemoglobin A. Anti-hemoglobin A, combined with antibodies against CD34, CD117, CD68, and MPO can be helpful in distinguishing between reactive extramedullary hematopoiesis and that seen in neoplastic myeloid disorders in spleen. Anti-hemoglobin A is limited to expression by erythroid precursors in bone marrow and is therefore of assistance in calculating percentages of erythroid precursors. Immunohistochemistry (IHC)
JAK2 Exon 12-14 Mutation Analysis

RT-PCR and bi-directional sequencing to detect non-V617F mutations in exons 12-14 and most of exon 15, corresponding to the majority of the JAK2 pseudokinase domain. Exon deletion mutations are detectable. Testing is performed on plasma for increased sensitivity whenever possible. V617F analysis is recommended before or concurrently with this test. Exon 12-14 Mutation Analysis may be ordered separately, with concurrent V617F testing, by reflex after negative V617F testing, or as part of the MPN Reflex Panel. Testing is approved for specimens from the state of New York.

Molecular
JAK2 V617F Mutation Analysis

Detects the V617F mutation. The rare mutation V617I is also detected. Testing is performed on plasma for increased sensitivity whenever possible. V617F testing may be ordered separately, concurrently with full exon 12-14 sequencing, with reflex to exon 12-14 sequencing, or as part of the MPN Reflex Panel. Testing is approved for specimens from the state of New York.

Molecular
Ki67

Ki67 is a nuclear protein that is expressed in proliferating cells. Ki67 is preferentially expressed during late G1, S, M, and G2 phases of the cell cycle, while cells in the G0 (quiescent) phase are negative for this protein. Increased proliferative activity is associated with more aggressive tumor and decreased disease-free survival period.
Note: Computer-assisted image analysis for Ki-67 is only validated for breast cancer and neuroendocrine carcinoma.

Immunohistochemistry (IHC)
LysozymeLysozyme is synthesized predominantly in reactive histiocytes rather than in resting, unstimulated phagocytes. This antibody labels myeloid cells, histiocytes, granulocytes, macrophages and monocytes. It is helpful in the identification of myeloid or monocytic nature of acute leukemia. Immunohistochemistry (IHC)
MPL Mutation Analysis

Bi-directional sequencing of exon 10 of the MPL gene to detect all possible mutations at the W515 and S505 codons, and other mutations throughout the exon. Testing is performed on plasma for increased sensitivity whenever possible. This test may be ordered separately or as part of the MPN Reflex Panel.

Molecular
MPN Extended Reflex Panel

Sequential testing panel including analysis of JAK2 V617F, JAK2 Exon 12-14, CALR exon 9, and MPL exon 10. Testing proceeds by reflex through the four-step panel until a mutation is identified, when the result is considered informative and no further testing is performed. Testing is performed on plasma for increased sensitivity whenever possible. Tests may also be ordered individually or as a three-step reflex panel without CALR in the MPN Standard Reflex Panel (see separate listing). Testing is approved for specimens from the state of New York. 

Molecular
MPN FISH Panel

Probes: PDGFRa, CHIC2, FIP1L1 (4q12) | PDGFRb (5q33) | FGFR1 (8p11) | BCR/ABL1 t(9;22) including ASS1 (9q34) | Probes may be ordered separately.
Disease(s): Myeloproliferative neoplasms

FISH
MPN Standard Reflex Panel

Sequential testing panel including analysis of JAK2 V617F, JAK2 Exon 12-14, and MPL exon 10. Testing proceeds by reflex through the three-step panel until a mutation is identified, when the result is considered informative and no further testing is performed. Testing is performed on plasma for increased sensitivity whenever possible. Tests may also be ordered separately. For reflex testing including CALR mutation analysis, please see the separate listing for MPN Extended Reflex Panel. Testing is approved for specimens from the state of New York. 

Molecular
MPOMyeloperoxidase (MPO) is an important enzyme used by granulocytes during phagocytic lysis of engulfed foreign particles. In normal tissues and in a variety of myeloproliferative disorders, myeloid cells of both neutrophilic and eosinophilic types, at all stages of maturation, exhibit strong cytoplasmic reactivity for MPO. MPO is useful in differentiating between myeloid and lymphoid leukemias. Immunohistochemistry (IHC)
MPO Cytochemical

Cytochemical stain. Myeloperoxidase (MPO) is present in granules of myeloid and monocytic cells, but absent from lymphocytes. Therefore MPO is an important marker for discriminating myeloid vs. lymphoid blasts. Staining is used to distinguish acute myeloid leukemia (AML) and other myeloid leukemias from lymphoid disorders.

Immunohistochemistry (IHC)
NeoARRAY™ SNP/Cytogenetic Profile

The NeoARRAY SNP/Cytogenetic Profile is available for hematological, solid tumor, and pregnancy loss indications. With the best genome-wide coverage available, this test employs an enhanced SNP microarray with over 2.6 million SNP and non-polymorphic markers for detection of copy number variants (deletions, duplications, and amplifications) and loss of heterozygosity or uniparental disomy (LOH or UPD) in any chromosome. Sensitivity and specificity for detection of copy number variants >400 kb is >99%. Testing may not reliably detect abnormalities present in less than 20% of the cells tested. Balanced rearrangements, including translocations and inversions, are not detectable by this method. Clients may request NeoARRAY on POC as the sole test, or they may order POC cytogenetics with reflex to NeoARRAY if the POC culture fails or if cytogenetic results are normal. For reflex orders, if there is no cell attachment or growth after 14 days in culture, a cytogenetics failure report will be issued and NeoARRAY will be performed. If there is limited cell attachment after 14 days in culture, NeoGenomics will contact the client for instructions. When array testing is not performed, a fee will be charged for DNA extraction (which is performed upon specimen receipt).

Molecular
NeoLAB™ Myeloid Disorders Profile - Liquid Biopsy

This test is performed on cell-free DNA/RNA in peripheral blood plasma by sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A (MLL), KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE JMML Profile

This test is performed by sequencing the entire coding regions of the genes listed. BRAF, CBL, CEBPA, FLT3, HRAS, JAK2 including V617F and Exons 12+14, JAK3, KIT, KRAS, NPM1, NRAS, PDGFRA, PTEN, PTPN11, and SETBP1. FLT3 is performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE MPN Profile

This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ABL1, ASXL1, BRAF, CALR, CEBPA, CSF3R, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2 including V617F and Exons 12+14, KIT, KRAS, MPL, NPM1, NRAS, PDGFRA, PTEN, PTPN11, SETBP1, SRSF2, TET2, and U2AF1. CALR and FLT3 are performed by multiple methods. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together.

Molecular
NeoTYPE Myeloid Disorders Profile

This test is performed by the sequencing the entire coding regions of the genes listed. ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2 including V617F and Exons 12+14, JAK3, KDM6A, KIT, KRAS, MLL, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2. CALR and FLT3 are performed by multiple methods. Test orders include summary interpretation of all results together.

Molecular
NRAS Exon 4 Mutation Analysis

Bi-directional sequencing of NRAS exon 4 is performed using PCR primers designed to target hotspot mutations in codons 117 and 146, among other regions in exon 4. Testing is available separately or in combination with BRAF, KRAS and HRAS in the RAS/RAF Panel. Testing is approved for specimens from the state of New York.

Molecular
NRAS Mutation Analysis

Bi-directional sequencing of NRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59, and 61. Testing is approved for specimens from the state of New York.

Molecular
PDGFRA RearrangementProbes: PDGFRA | CHIC2 | FIP1L1 (4q12) Disease(s): Chronic eosinophilic leukemia, MPN FISH
Periodic Acid Schiff (PAS)- HEMESpecial stain. Immunohistochemistry (IHC)
PTPN11 Mutation Analysis

Bi-directional sequencing of exons 2-4 of PTPN11.

Molecular
SETBP1 Mutation Analysis

Bi-directional sequencing of the SETBP1 exon 4 mutation hotspot (covering amino acids 823-941). The locked nucleic acid (LNA) technique is used to increase detection sensitivity for mutations at D868, G870, I871, and D880.

Molecular
SF3B1 Mutation Analysis

RT-PCR and bi-directional sequencing of exons 14-17 of the SF3B1 gene. More than 90% of reported mutations are detected in these exons. This test detects mutations present at 10-15% or more in a wild-type background.

Molecular
SRSF2 Mutation Analysis

Bi-directional sequencing of the mutation hotspot region in exon 1 of the SRSF2 gene corresponding to amino acids 57-120.

Molecular
Standard Leukemia/Lymphoma Panel - 24 markers

Available as global and tech-only. Markers are CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD13, CD14, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-DR, kappa, and lambda.

Flow Cytometry
U2AF1 Mutation Analysis

Bi-directional sequencing of exons 2 and 7 of the U2AF1 gene (also called U2AF35).

Molecular
Universal Fusion/Expression Profile

The Universal Fusion/Expression Profile is a targeted RNA sequencing panel that utilizes next-generation sequencing (NGS) to detect all relevant fusion transcripts in 1,385 genes associated with hematologic or solid tumor cancers. It is especially useful for testing patients with rare diseases. Learn more about the Universal Fusion/Expression Profile. See the full 1,385 gene list here.

Molecular
Wright GiemsaCytochemical stain. The Wright Giemsa stain is used to stain peripheral blood and bone marrow smears for study of blood cell morphology. Immunohistochemistry (IHC)
ZRSR2 Mutation Analysis

Bi-directional sequencing of exons 5 and 7-11 of the ZRSR2 gene.

Molecular